Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Announcement & Circular
Stock Information
02186.HK
1.87 -0.06  (-2.86%)
Volume：23,020,000
09-04
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026
Publisher：
08-30
2026
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
Publisher：
08-20
2026
VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO PHASE II CLINICAL TRIAL IN CHINA
Publisher：
08-17
2026
NOTICE OF BOARD MEETING
Publisher：
08-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
Publisher：
08-05
2026
VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF A U.S. BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
Publisher：
07-06
2026
COMPLETION OF EARLY REDEMPTION OF OUTSTANDING US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028
Publisher：
07-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026
Publisher：
06-26
2026
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026
Publisher：
06-16
2026
VOLUNTARY ANNOUNCEMENT THE PHASE 2 CLINICAL TRIAL IN CHINA OF THE GROUP'S NEW DRUG LY03015 (A VMAT2 INHIBITOR/SIGMA-1R AGONIST) FOR THE TREATMENT OF TARDIVE DYSKINESIA HAS ACHIEVED ...
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Stock Information
02186.HK
Volume：23,020,000
1.87
-0.06  (-2.86%)
Announcement & Circular
09-04
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026
08-30
2026
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
08-20
2026
VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO PHASE II CLINICAL TRIAL IN CHINA
08-17
2026
NOTICE OF BOARD MEETING
08-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
08-05
2026
VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF A U.S. BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
07-06
2026
COMPLETION OF EARLY REDEMPTION OF OUTSTANDING US$180,000,000 6.25 PER CENT. CONVERTIBLE BONDS DUE 2028
07-06
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026
06-26
2026
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026
06-16
2026
VOLUNTARY ANNOUNCEMENT THE PHASE 2 CLINICAL TRIAL IN CHINA OF THE GROUP'S NEW DRUG LY03015 (A VMAT2 INHIBITOR/SIGMA-1R AGONIST) FOR THE TREATMENT OF TARDIVE DYSKINESIA HAS ACHIEVED POSITIVE RESULTS
First
1
2
3
4
5
Last